Vanda Pharmaceuticals (VNDA) Revenue (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Revenue data on file, last reported at $51.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 3.35% year-over-year to $51.7 million; the trailing twelve-month figure through Mar 2026 stood at $217.8 million (up 8.16% YoY), and the FY2025 full-year result was $216.1 million, up 8.72% from the prior year.
• Revenue retreated to $51.7 million in Q1 2026, from $57.2 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $65.3 million in Q3 2022 to a low of $38.8 million in Q3 2023.
• A 5-year average of $53.7 million and a median of $52.6 million in 2025 frame the typical range for Revenue.
• Across the five-year window, Revenue plunged 40.58% in 2023 and advanced 22.76% in 2024, its largest moves.
• Tracing VNDA's Revenue over 5 years: stood at $64.5 million in 2022, then decreased by 29.79% to $45.3 million in 2023, then climbed by 17.48% to $53.2 million in 2024, then rose by 7.58% to $57.2 million in 2025, then fell by 9.61% to $51.7 million in 2026.
• Business Quant data shows VNDA's Revenue at $51.7 million in Q1 2026, $57.2 million in Q4 2025, and $56.3 million in Q3 2025.